Skip to main content
. 2020 May 27;21(11):3794. doi: 10.3390/ijms21113794

Figure 6.

Figure 6

Leptin increases survival of chemoresistant triple-negative breast cancer cells treated with paclitaxel and cisplatin. (A) Paclitaxel and (B) cisplatin dose–response effects on survival of MDA-MB231 VBL-100 breast cancer cells. Cells were treated with paclitaxel (P, 10−4–102 μM) or cisplatin (C, 10−4–102 μM); P or C + Leptin (L, 2.5 nM) and P or C + L + C6 and mC6 leptin antagonists (2.5 nM) for 72 h. CellTiter-Glo Assay was used to determine relative cell survival; “a”: p ≤ 0.05 compared to P; “b”: p ≤ 0.05 compared to P + L; “c”: p ≤ 0.05 compared to C; “d”: p ≤ 0.05 compared to C + L.